News archives


OCTOBER - DECEMBER 17

JULY - SEPTEMBER 17

APRIL - JUNE 17

JANUARY - MARCH 17

OCTOBER - DECEMBER 16

JULY - SEPTEMBER 16

APRIL - JUNE 16

JANUARY - MARCH 16

OCTOBER - DECEMBER 15

JULY - SEPTEMBER 15

APRIL - JUNE 15

JANUARY - MARCH 15

OCTOBER - DECEMBER 14

JULY - SEPTEMBER 14

APRIL - JUNE 14

JANUARY - MARCH 14

OCTOBER - DECEMBER 13

JULY - SEPTEMBER 13

APRIL - JUNE 13

JANUARY - MARCH 13

OCTOBER - DECEMBER 12

JULY - SEPTEMBER 12

APRIL - JUNE 12

JANUARY - MARCH 12

OCTOBER - DECEMBER 11

JULY - SEPTEMBER 11

APRIL - JUNE 11

JANUARY - MARCH 11

OCTOBER - DECEMBER 10

JULY - SEPTEMBER 10

APRIL - JUNE 10

JANUARY - MARCH 10

OCTOBER - DECEMBER 09

JULY - SEPTEMBER 09

APRIL - JUNE 09

JANUARY - MARCH 09

OCTOBER - DECEMBER 08

JULY - SEPTEMBER 08

APRIL - JUNE 08

JANUARY - MARCH 08

OCTOBER - DECEMBER 07

JULY - SEPTEMBER 07

APRIL - JUNE 07

JANUARY - MARCH 07

 
  current news   Press   selected story    
     
  30th October  
  Prof Neal Copeland appointed IMCBs Executive Director
 
 




Professor Copeland has been appointed Executive Director (ED) of IMCB from 5 November 2007. He joined IMCB in 2006 after spending more than 30 years in leading laboratories in the United States, including an illustrious 20-year career at the National Cancer Institute of the NIH (National Institutes of Health). He is ranked among the world’s top 50 most-cited biomedical scientists and has published more than 750 papers and has been cited more than 30,000 times. His pioneering work on discovering a way to accelerate the identification of cancer-causing genes in mice, which he did together with his wife, Professor Nancy Jenkins, Deputy Director IMCB.

Professor Copeland will build on the strong foundation and deep scientific capabilities at the IMCB, which marks its 20th anniversary this year. The institute was set up in 1987 as Singapore’s first foray into life sciences research with just 12 research staff and 24 graduate students. IMCB now has a strength of more than 400 research staff running 40 laboratories in the areas of cell and developmental biology, cancer genetics and translational research. IMCB also has core strengths in cell cycling, cell signalling, cell death, cell motility and protein trafficking. IMCB scientists have published over 1500 research papers in top international journals in the last 20 years.

Professor Copeland takes over from Professor Sir David Lane, who served as Chairman of IMCB’s Scientific Advisory Board from 2002 and as IMCB Executive Director (ED) since August 2004. Professor Lane holds a concurrent appointment at the University of Dundee in Scotland. Professor Copeland said, "It's a privilege for me to carry the baton of Singapore's oldest biomedical research institute. I intend to work with my colleagues to build on the initiatives David started to integrate and translate IMCB's solid scientific work into clinical applications. In particular, we will strengthen disease-focused research in areas such as cancer, inflammatory diseases and cardiovascular disease and further establish our expertise in animal models to better understand human diseases. We will underpin these translational efforts with basic scientific research of the highest standards and on developing and attracting the best scientific talent as the bedrock of IMCB."

For more information, click here to read the full press release.